In a milestone that could reshape the future of neurotechnology, China has approved what is described as the world’s first invasive brain-computer interface for clinical use beyond trials, signaling a decisive shift from laboratory experimentation to regulated medical deployment. The development, reported by MIT Technology Review, places China at the forefront of a rapidly evolving field that blends neuroscience, engineering, and artificial intelligence to restore lost motor function in patients with severe paralysis. While the technology is still in its early stages, the approval marks a turning point in how brain implants may soon move from exceptional cases to broader therapeutic use.
At the center of this breakthrough is a 39-year-old patient named Dong Hui, whose life was transformed after a car accident left him paralyzed from the neck down. After years of limited mobility, Dong enrolled in a clinical trial in late 2024 for an invasive brain-computer interface developed in China. Months later, he became one of the first individuals to use the device in daily rehabilitation outside strictly controlled experimental settings. During a recent recovery session in Henan province, Dong was able to write his name and simple words again, a symbolic and emotional achievement that underscored the system’s potential to restore basic independence. His experience, while individual, is now being positioned as a preview of a broader clinical future.
The device enabling this recovery is a coin-sized implant known as NEO, developed by Neuracle Technology in collaboration with researchers at Tsinghua University. Unlike more invasive systems that penetrate brain tissue, NEO is positioned on the dura mater, the protective membrane surrounding the brain. It captures neural signals and transmits them to an external computer system, which translates them into commands for assistive devices such as a robotic glove. The system requires intensive daily training, during which patients learn to convert thought patterns into physical actions through assisted feedback loops.
Dong’s rehabilitation illustrates how quickly adaptation can occur once the interface is installed. Within days of surgery, he began structured training sessions lasting several hours per day. In one early breakthrough, he successfully grasped an object without the robotic glove assisting him, suggesting that neural pathways could be reinterpreted through sustained use of the device. Although he still relies on support systems, Dong has continued practicing at home with the goal of regaining the ability to perform basic tasks such as eating and dressing without assistance. His progress highlights both the promise and the limits of current brain-computer interface technology, which remains dependent on structured rehabilitation environments.
In March, Chinese regulators approved NEO for broader clinical application, making it the first invasive brain-computer interface in the world to receive such authorization beyond trials. The approval was issued by China’s National Medical Products Administration, the country’s central drug and medical device regulator. According to MIT Technology Review, the system is currently intended for adults aged 18 to 60 with spinal cord injuries that have resulted in full limb paralysis but who retain some residual upper limb function. The approval places the technology in a carefully defined patient category, signaling a cautious but meaningful step toward wider deployment.
The regulatory pathway for NEO appears to have been significantly faster than comparable efforts elsewhere. Experts cited in the report suggest that its design may have contributed to this acceleration. Unlike systems such as Neuralink’s N1 device, which penetrates the brain cortex directly, NEO’s sensors rest on the brain’s outer protective layer, reducing risks such as hemorrhage and long-term tissue damage. Researchers including Avinash Singh from the University of Technology Sydney note that this relatively less invasive approach likely placed the device in a lower-risk regulatory category, enabling faster clinical review and approval.
China’s broader policy environment has also played a decisive role. Unlike regulatory systems that can take years to evaluate novel neurotechnology, China has actively prioritized brain-computer interfaces as a strategic sector. Strong government backing, combined with streamlined approval mechanisms, has helped accelerate clinical trials and manufacturing readiness. Following approval, NEO was quickly assigned a health insurance code, an early step toward partial reimbursement for eligible patients. This integration suggests an intention not only to develop the technology but also to embed it within the national healthcare system.
The implications extend beyond a single device. Experts quoted by MIT Technology Review, including neuroscientist Wang Shouyan of Fudan University, argue that NEO’s approval signals a transition from experimental neuroscience to scalable medical technology. After decades of laboratory-based research, brain-computer interfaces are now approaching a stage where they can be manufactured, distributed, and used in clinical settings. This shift could significantly expand access for patients with spinal injuries or neurodegenerative conditions, while also reshaping expectations about long-term rehabilitation.
China’s strategic ambitions are reinforced by national policy direction. Brain-computer interfaces were recently listed among priority technologies in the country’s five-year development plan, alongside fields such as quantum computing and humanoid robotics. Several domestic companies and research institutes are already working on competing systems, including devices that target both motor and speech impairments. Analysts suggest that additional approvals could follow within the next few years, further expanding the clinical landscape for neurotechnology in China.
Despite the momentum, researchers caution against framing developments as a geopolitical race. Neuroscientist Nick Ramsey of Radboud University Nijmegen argues that brain-computer interface development does not have a clear endpoint, making comparisons between countries inherently limited. Instead, experts emphasize that China and the United States may be pursuing different models of innovation. While US efforts often focus on achieving peak technical performance, China appears to be prioritizing scalability and real-world accessibility, even if performance metrics differ.
This divergence has not prevented collaboration entirely. According to the report, some US-based neurotechnology companies have already partnered with Chinese institutions for clinical trials, reflecting the fact that scientific cooperation persists even amid broader geopolitical tension. Such partnerships suggest that neurotechnology remains one of the few fields where cross-border research continues to function through shared medical goals rather than political alignment.
Looking ahead, additional brain-computer interface systems are already under regulatory review in China, including Beinao-1, developed by the Chinese Institute for Brain Research and its affiliated startup NeuCyber NeuroTech. Like NEO, it is designed to assist patients with spinal cord injuries and motor disorders, with potential applications extending to speech restoration. If approved, it could further accelerate the integration of neural implants into mainstream medical treatment pathways.
For patients like Dong Hui, however, these developments are not abstract milestones but immediate transformations in lived experience. Each successful movement represents a reclaiming of autonomy that once seemed permanently lost. As MIT Technology Review notes, the significance of NEO’s approval lies not only in technological achievement but in the possibility that brain-computer interfaces may soon move from rare experimental interventions to widely available medical tools. Whether this future arrives quickly or gradually, China’s decision marks a clear signal that the era of clinical neurotechnology has begun to enter a new phase of scale.
